Google_______________

Serosorting Could Potentially Increase HIV Transmission if Individuals Do Not Accurately Know their HIV Status

By Liz Highleyman

Serosorting -- a practice in which people have unprotected intercourse only with others of the same HIV serostatus -- has been proposed by some harm reduction advocates as a way to reduce the risk of HIV transmission.

But the benefits of serosorting are only as good as the accuracy of a partner's serostatus disclosure, and a new mathematical model suggests that it may actually increase the risk of transmission in some circumstances, since recently infected individuals may still believe they are HIV negative.

"The effectiveness of a serosorting strategy for HIV prevention depends on the accuracy of individuals' serostatus disclosures," researchers from the University of California at San Diego wrote in the May 31, 2007 issue of AIDS. "We modeled the risks of sexual transmission of HIV under various circumstances differing by the type of disclosures made. Accounting for rates of unrecognized HIV infection, treatment status, and differences in infectivity by stage of infection, we found that serosorting can increase the transmission risk for some groups."

Newly infected individuals are of particular concern, since acute or primary HIV infection is associated with very high viral loads and a high degree of infectiousness. One recent study, for example, found that about half of all new infections may be transmitted by people with acute infection.

Not only are viral loads high during the earliest stages of infection, but most people are not aware they are infected. They may have become infected since their last test, or may have been tested during the "window period" before the body has had a chance to produce enough antibodies to be detected by the test. Thus, such individuals may inadvertently inform a potential sex partner that they are HIV negative when this is no longer the case.

According to the mathematical model, the benefits of serosorting decrease as the proportion of recently infected individuals in a population of potential sex partners increases. Indeed, an HIV negative person may actually be at less risk from having sex with a known HIV positive partner with chronic infection (especially if they are receiving effective antiretroviral therapy) than with a supposedly HIV negative partner who actually has acute infection.

"The effectiveness of serosorting on the basis of mutual disclosure of perceived HIV status is a flawed strategy for reducing sexual transmissions of HIV when it does not consider the prevalence of recent HIV infections in specific populations," the authors wrote. " By ignoring the increased potential for HIV transmission by recently infected individuals, serosorting may paradoxically increase the number of new HIV infections in certain populations."

06/15/07

Reference
DM Butler and DM Smith. Serosorting can potentially increase HIV transmissions. AIDS 21(9): 1218-1220. May 31, 2007.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Index of All HIV and AIDS
Articles by Topic ( A to Z)


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)